

Mainstay Medical Strengthens Board with New Independent Director

DUBLIN--([BUSINESS WIRE](#))-- Regulatory News:

Mainstay Medical International plc ("Mainstay" or the "Company" listed on Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE) announces the appointment of Mr James A. Reinstein as an additional independent Director with immediate effect. Mr Reinstein brings a wealth of international knowledge and commercial expertise from a career of over twenty five years in the medical device industry.

Mr. Reinstein is currently President and CEO of Aptus Endosystems, a medical device company based in California. Prior to that he was Senior Vice President and Chief Commercial Officer of Cyberonics Inc., a leading medical device company in neuromodulation, and before that he had a distinguished 17 year career working for Boston Scientific, including serving as European Division Head of the Neurovascular Division based in Paris, France, where he lived for four years. Mr. Reinstein's educational background is in Business, including completing an Executive Management Program at INSEAD in France.

Commenting on his appointment Mr Reinstein said, *"I am extremely excited to be joining Mainstay's Board of Directors. The Mainstay team has done an impressive job developing ReActiv8 for the large group of patients suffering from chronic low back pain and I look forward to adding value to this Company"*.

Welcoming Mr Reinstein's appointment, Mainstay Medical's Chairman Dr Oern Stuge said, *"We are delighted to have James join our Board. His background and experience add a complementary perspective as an independent Director of the Board"*.

- End -

Additional Information:

Mr. James A. Reinstein (aged 50) holds no shares in Mainstay, and, other than as set out below, there is no further information to be disclosed under schedule 2(g) and Rule 17 of the ESM Rules in respect of Mr. Reinstein's appointment as a Non-Executive Director.

Mr. Reinstein is, or has been, a director of the following companies during the previous five years:

Current Directorships Past Directorships within last 5 years

Aptus Endosystems Inc.

About Mainstay

Mainstay is a medical device company which is developing an innovative implantable neurostimulation medical device, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). Low Back Pain is a leading cause of activity limitation and work absence throughout much of the developed world, imposing a high economic burden on individuals, families, communities, industry, and governments.

The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States and Australia, and is listed on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the lower back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or

anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on economies.

Further information can be found at www.mainstay-medical.com.

ReActiv8 is an investigational device and is not approved for commercialisation anywhere in the world.

CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.

Forward looking statements

This announcement includes statements that are, or may be deemed to be, forward looking statements. These forward looking statements can be identified by the use of forward looking terminology, including the terms “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “should” or “will”, or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward looking statements include all matters that are not historical facts. They appear throughout this announcement and include, but are not limited to, statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s results of operations, financial position, prospects, financing strategies, expectations for product design and development, regulatory applications and approvals, reimbursement arrangements, costs of sales and market penetration.

By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward looking statements are not guarantees of future performance and the actual results of the Company’s operations, and the development of the markets and the industry in which the Company operates, may differ materially from those described in, or suggested by, the forward looking statements contained in this announcement. In addition, even if the Company’s results of operations, financial position and growth, and the development of the markets and the industry in which the Company operates, are consistent with the forward looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments of the Company to differ materially from those expressed or implied by the forward looking statements including, without limitation, general economic and business conditions, the global medical device market conditions, industry trends, competition, changes in law or regulation, changes in taxation regimes, the availability and cost of capital, the time required to commence and complete clinical trials, currency fluctuations, changes in its business strategy, political and economic uncertainty. The forward-looking statements herein speak only at the date of this announcement.

Contacts

Media queries:

Jonathan Neilan, FTI Consulting

Tel: +353 1 663 3686

Email: jonathan.neilan@fticonsulting.com

or

Astrid Villette, FTI Consulting (French language enquiries)

Tel: +33 1 47 03 69 51

Email: Astrid.Villette@fticonsulting.com

or

Investor relations:

Jillian Connell, The Trout Group LLC

Tel: +1 646 378 2956 / +1 617 309 8349

Email: jconnell@troutgroup.com

or

ESM Advisers:

Fergal Meegan or Barry Murphy, Davy

Tel: +353 1 6796363

Email: fergal.meegan@davy.ie or
barry.murphy2@davy.ie

Source: Mainstay Medical